Saad Z. Usmani

Saad Z. Usmani is the clinical leader who brought teclistamab from first-in-human testing to FDA approval as the first BCMA-targeted bispecific antibody. As Chief of Myeloma Service at Memorial Sloan Kettering, he leads one of the world's largest myeloma programs. His first authorship on the MajesTEC-1 Lancet 2021 paper established teclistamab's efficacy in heavily pretreated patients, directly leading to FDA approval in October 2022. He received the 2021 Bart Barlogie Young Investigator Award from the International Myeloma Society. Usmani continues pioneering combination bispecific strategies, including dual teclistamab/talquetamab approaches for resistant disease.

Saad Z. Usmani博士是将teclistamab从首次人体试验推进到FDA批准的临床领导者，使其成为首个BCMA靶向双特异性抗体。作为纪念斯隆凯特琳癌症中心骨髓瘤服务主任，他领导世界最大的骨髓瘤项目之一。他作为MajesTEC-1 Lancet 2021论文的第一作者，确立了teclistamab在重度预治疗患者中的疗效，直接促成2022年10月FDA批准。他获得2021年国际骨髓瘤学会Bart Barlogie青年研究者奖。Usmani继续开创联合双特异性抗体策略，包括用于耐药疾病的双teclistamab/talquetamab方案。